The non-viral drug delivery systems market has gained immense popularity owing to its wide applications in developing efficient gene therapies. Non-viral vectors offer certain advantages over viral vectors such as enhanced safety, less immunogenicity, potential for large cargo, and capacity for repetitive administration. Non-viral drug delivery systems help in encapsulation or conjugation of therapeutic agents such as proteins, nucleic acids, and small molecules. They protect the active pharmaceutical ingredient from degradation and targeted delivery to the site of action.
The Non-Viral Drug Delivery Systems Market is estimated to be valued at US$ 8.1 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024-2031.
Key drivers of the non-viral drug delivery systems market include the growing demand for advanced drug delivery technologies that can efficiently transfer the therapeutic genetic materials into target cells. The non-viral systems have gained prominence due to their ability to deliver larger nucleic acid payloads and flexibility in modifying their structure. Technological advancements in developing efficient non-viral vectors is another major factor fueling the market growth.
Key Takeaways
Key players operating in the non-viral drug delivery systems are Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, and eTheRNA Immunotherapies. These players are focused on developing innovative non-viral platforms for nucleic acid delivery in various disease treatments.
There is significant scope for market expansion in disease indications such as cancer, genetic disorders, infectious diseases, and ophthalmic diseases where non-viral drug delivery systems can be utilized. Continuous research on modifying non-viral vectors to enhance their efficiency, reduce cytotoxicity, and loading capacity would open up new application avenues.
Major players are actively pursuing global expansion strategies through collaborations and partnerships. For instance, in 2021 CureVac partnered with GlaxoSmithKline for mRNA vaccine development and manufacturing. Similarly, eTheRNA Immunotherapies collaborated with Boehringer Ingelheim to develop mRNA-based cancer immunotherapies. Such deals help companies strengthen their geographical presence.
Key market restrain include challenges in developing non-viral systems that can efficiently cross biological barriers such as the cell membrane and endosomal escape. Lower transfection efficiency compared to viral vectors is another concern. Nonetheless, continuous R&D is expected to overcome these limitations in the coming years.
Market Drivers And Restrain:
The major market driver is the wide applications of non-viral drug delivery systems in developing efficient gene therapies. They offer advantages over viral vectors such as enhanced safety, less immunogenicity and potential for large cargo delivery. The growing demand for advanced drug delivery technologies is also fueling the market growth.
The key market restrain is challenges in developing non-viral systems that can efficiently cross biological barriers and demonstrate higher transfection efficiency comparable to viral vectors. However, ongoing research and technological developments are expected to address these limitations.
Segment Analysis
The Non-Viral Drug Delivery Systems market can be segmented based on route of administration, technology, application, and end user. The largest sub-segment in the route of administration segment is oral drug delivery, due to its ease of use. Oral administration leads to better patient compliance as compared to other routes of administration like injectable, pulmonary, and others.
In the technology segment, the lipid-based drug delivery sub-segment dominates, owing to its ability to safely encapsulate both hydrophilic and hydrophobic therapeutics. This helps in improving their pharmacokinetics and increasing their therapeutic efficacy. Furthermore, the cancer application sub-segment accounts for the majority share in the application segment. Growing prevalence of cancer and increasing R&D for targeted drug delivery for cancer therapy treatment are some factors driving growth of this sub-segment.
In terms of end users, the pharmaceutical industry holds the highest market share. Increasing approvals for non-viral gene therapeutics and collaboration between drug delivery companies and pharma firms for developing advanced therapies are some factors propelling growth of this end-user segment.
Global Analysis
North America is expected to dominate the Non-Viral Drug Delivery Systems Market during the forecast period. This is attributed to factors such as rising healthcare expenditures, growing trend of self-administration of drugs, presence of major players, and technological advancement in the region. Europe is anticipated to showcase substantial growth due to significant funding for research projects involving drug delivery technologies by government bodies.
Asia Pacific is projected to witness highest growth rate over the forecast period. The increasing geriatric population which is more prone to develop chronic diseases, rise in healthcare spending, and growing medical tourism are some factors expected to boost market growth in Asia Pacific. Latin America and Middle East & Africa are likely to offer lucrative opportunities for market players owing to rising investment by pharmaceutical giants for generics and biosimilar development in these regions.
Get more insights on this topic: https://www.dailyprbulletin.com/the-rise-of-non-viral-drug-delivery-systems-is-promoting-customized-medicines/
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)
What Are The Key Data Covered In This Non-Viral Drug Delivery Systems Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the Non-Viral Drug Delivery Systems Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the Non-Viral Drug Delivery Systems Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- Non-Viral Drug Delivery Systems Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of Non-Viral Drug Delivery Systems Market vendors
FAQ’s
Q.1 What are the main factors influencing the Non-Viral Drug Delivery Systems Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top Non-Viral Drug Delivery Systems Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the Non-Viral Drug Delivery Systems Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it